DNA fundamentally reshaped medicine because it answered one of the most important questions in modern biology: What could happen to this patient or why did this happen to this patient? It revealed inherited susceptibility, acquired mutations, and the genomic events that influence human health.
As molecular diagnostics has matured, the questions clinicians ask have naturally evolved into a focus on real-time information that is necessary for taking clinical action. These questions require insight into biological behavior rather than biological possibility, and those answers are often encapsulated in RNA.
Rather than describing what biology permits, or may influence sometime in the future, gene expression provides access to what biology is actively doing now. It reveals cellular activities as they unfold, capturing immune engagement, tissue response, metabolic adaptation, and the dynamic communication between disease and its host. This evolution from static information to real-time activity reflects the natural progression of the questions molecular diagnostics are now capable of answering.
While DNA allows clinicians to answer fundamental questions around the molecular basis of disease, RNA offers information on what a disease is doing right now. Ultimately, the most important information actually answers a different question, “What do I do next?”
The natural progression of molecular diagnostics should be to move toward answering ever-more important biological questions—in other words, the questions that prioritize actionable patient outcomes over the total amount of biological data gathered.
Rethinking What Early Detection Actually Measures
If asking more immediately relevant biological questions is the defining challenge of the next chapter of molecular diagnostics, early cancer detection is likely where that change will become most apparent and impactful.
Early detection has largely been framed as an analytical problem. The underlying assumption has been straightforward. Early tumors shed very little material, making them inherently difficult to detect. Much of the field has therefore focused on increasing analytical sensitivity by identifying progressively smaller amounts of tumor-derived DNA.
This brings about a different biological question: What if the limiting factor is not simply how much tumor material exists? What if the more important question is whether we are measuring the biology that changes earliest and in a way that can influence clinical management most meaningfully?
The scientific reality is that even the smallest tumor is biologically active. Long before it becomes clinically apparent, it is altering transcription, engaging the immune system, reshaping its surrounding microenvironment, influencing metabolism, and communicating with tissues throughout the body. In other words, the physical mass may be small while the biological consequence is already measurable.
Therefore, we should ask which biological processes become abnormal earliest. More importantly, we want to know which of those changes most reliably distinguish meaningful disease from normal physiology, while also providing information that changes what clinicians do next.
Earlier insight becomes valuable only when it enables earlier action. This could mean directing imaging options, informing biopsy decisions, initiating therapy sooner, or avoiding unnecessary intervention.
The goal of early detection has never been simply to find cancer sooner. It has been to create an opportunity to intervene sooner. Detection is not the endpoint. Clinical action is.
What Makes a Diagnostic Valuable?
If early detection is ultimately measured by the clinical decisions it enables, then perhaps diagnostics themselves should be evaluated the same way. For much of molecular medicine, progress has understandably been measured by the amount of biology we could interrogate. Yet the most successful diagnostics are not necessarily those that generate the greatest amount of information. They are often the ones that provide actionable information for clinicians and patients. Importantly, they must do it accurately, reproducibly, and in the moment it can most meaningfully influence patient care.
The Future of Molecular Diagnostics
Transformative discoveries often achieve their greatest impact not when they become more sophisticated, but when they make clinically actionable decisions more accessible. Molecular diagnostics will be no different. Clinical utility, affordability, scalability, and accessibility are not competing priorities; they are the mechanisms through which scientific discovery translates into patient care.
Perhaps the next frontier will be focused on clinical information density, maximizing clinical insight while minimizing unnecessary biological complexity. This redefines the concept of scientific achievement from measuring the most biology to identifying the smallest amount of biology capable of unlocking the earliest clinically actionable information. Sometimes the greatest scientific advances do not emerge from seeing more, but from seeing what matters.
